924 related articles for article (PubMed ID: 29906595)
21. Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract.
He G; Wu L; Zheng Q; Jiang X
Ann Med; 2022 Dec; 54(1):2500-2510. PubMed ID: 36120867
[No Abstract] [Full Text] [Related]
22. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K
Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
[TBL] [Abstract][Full Text] [Related]
23. Antimicrobial susceptibility and molecular characterization of Mycobacterium intracellulare in China.
Zhao X; Wang Y; Pang Y
Infect Genet Evol; 2014 Oct; 27():332-8. PubMed ID: 25131955
[TBL] [Abstract][Full Text] [Related]
24. In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.
Brown-Elliott BA; Philley JV; Griffith DE; Thakkar F; Wallace RJ
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872065
[TBL] [Abstract][Full Text] [Related]
25. Comparing the Genotype and Drug Susceptibilities between Mycobacterium avium and Mycobacterium intracellulare in China.
Zheng HW; Pang Y; He GX; Song YY; Zhao YL
Biomed Environ Sci; 2017 Jul; 30(7):517-525. PubMed ID: 28756811
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic drug-susceptibility profiles and genetic analysis based on whole-genome sequencing of Mycobacterium avium complex isolates in Thailand.
Sirichoat A; Kaewprasert O; Hinwan Y; Faksri K
PLoS One; 2023; 18(11):e0294677. PubMed ID: 37992075
[TBL] [Abstract][Full Text] [Related]
27. In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates.
Lin S; Hua W; Wang S; Zhang Y; Chen X; Liu H; Shao L; Chen J; Zhang W
BMC Microbiol; 2022 Jul; 22(1):175. PubMed ID: 35804298
[TBL] [Abstract][Full Text] [Related]
28. Evaluating amikacin minimum inhibitory concentration in trailing growth for Mycobacterium avium complex.
Park B; Shim TS; Jo KW; Won EJ; Kim MN; Sung H
Tuberculosis (Edinb); 2023 Dec; 143():102427. PubMed ID: 37918057
[TBL] [Abstract][Full Text] [Related]
29.
Litvinov V; Makarova M; Kudlay D; Nikolenko N; Mikhailova J
J Med Microbiol; 2021 Oct; 70(10):. PubMed ID: 34668850
[No Abstract] [Full Text] [Related]
30. Comparison of in vitro synergistic effect between clarithromycin or azithromycin in combination with amikacin against Mycobacterium intracellulare.
Zhang Z; Lu J; Du Y; Xie F; Wang Y; Sun B; Pang Y
J Glob Antimicrob Resist; 2019 Sep; 18():183-186. PubMed ID: 30953831
[TBL] [Abstract][Full Text] [Related]
31. Rational Choice of Antibiotics and Media for
Jaffré J; Aubry A; Maitre T; Morel F; Brossier F; Robert J; Sougakoff W; Veziris N;
Front Microbiol; 2020; 11():81. PubMed ID: 32140138
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of phenotypic and genotypic antibiotic susceptibility patterns in Mycobacterium avium complex.
Wetzstein N; Kohl TA; Andres S; Schultze TG; Geil A; Kim E; Biciusca T; Hügel C; Hogardt M; Lehn A; Vehreschild MJGT; Wolf T; Niemann S; Maurer FP; Wichelhaus TA
Int J Infect Dis; 2020 Apr; 93():320-328. PubMed ID: 32147539
[TBL] [Abstract][Full Text] [Related]
33. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to new macrolides, new quinolones, and antituberculous drugs on Dubos agar medium].
Ogawa K; Miwa T; Sasamoto M; Sasaki T; Tsuda M; Honda K; Furui H; Torii K; Takagi K
Kekkaku; 1992 Nov; 67(11):735-8. PubMed ID: 1487866
[TBL] [Abstract][Full Text] [Related]
34. Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin? Canadian HIV Trials Network Protocol 010 Study Group.
Shafran SD; Talbot JA; Chomyc S; Davison E; Singer J; Phillips P; Salit I; Walmsley SL; Fong IW; Gill MJ; Rachlis AR; Lalonde RG
Clin Infect Dis; 1998 Dec; 27(6):1401-5. PubMed ID: 9868650
[TBL] [Abstract][Full Text] [Related]
35. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
[TBL] [Abstract][Full Text] [Related]
36. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.
Koga T; Fukuoka T; Doi N; Harasaki T; Inoue H; Hotoda H; Kakuta M; Muramatsu Y; Yamamura N; Hoshi M; Hirota T
J Antimicrob Chemother; 2004 Oct; 54(4):755-60. PubMed ID: 15347635
[TBL] [Abstract][Full Text] [Related]
37. Usefulness of various antibiotics against Mycobacterium avium-intracellulare, measured by their mutant prevention concentration.
Rodríguez JC; Cebrián L; López M; Ruiz M; Royo G
Int J Antimicrob Agents; 2005 Mar; 25(3):221-5. PubMed ID: 15737516
[TBL] [Abstract][Full Text] [Related]
38. [Macrolide and linezolid susceptibility testing for Mycobacterium intracellulare isolates].
Duan H; Liang Q; Chu N; Huang H
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Apr; 37(4):266-9. PubMed ID: 24969714
[TBL] [Abstract][Full Text] [Related]
39. Susceptibility of Mycobacterium avium and Mycobacterium intracellulare to various antibacterial drugs.
Tomioka H; Sato K; Saito H; Yamada Y
Microbiol Immunol; 1989; 33(6):509-14. PubMed ID: 2770562
[TBL] [Abstract][Full Text] [Related]
40. Isolation and characterizations of clarithromycin-resistant Mycobacterium avium clinical isolates.
Lee SH; Park YK; Kim CK; Kim HJ
J Clin Lab Anal; 2011; 25(1):33-6. PubMed ID: 21254240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
